MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leader in cancer diagnostics, today announced the launch of the Cancerguard™ test, a new multi-cancer early detection (MCED) ...
Exact Sciences has launched its long-awaited blood test designed to detect the early stages of multiple tumors, with a plan to sell it to consumers through a telehealth program in a bid to increase ...
A foundational guide for stage 2 prostate cancer clarifies staging implications, localized-disease management, and trade-offs among surgery, radiation, and quality-of-life outcomes to support informed ...
Study aims to understand the effectiveness and use of multi-cancer detection blood tests SEATTLE – July 15, 2025 – Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national ...
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made ...
New Orleans - The Ochsner Cancer Institute is proud to announce its participation in a pivotal research study that evaluates the real-world performance of the Galleri® multi-cancer early detection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results